m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0253)
| Name |
GLYCYRRHIZIN
|
||||
|---|---|---|---|---|---|
| Synonyms |
Glycyrrhizic acid; Glycyrrhizinic acid; 1405-86-3; Glycyron; Glycyrrhetinic acid glycoside; glyzyrrhizin; 18-beta-Glycyrrhizic acid; Glycyrrizin; Liquorice; UNII-6FO62043WK; Rizinsan K2 A2 (free acid); HSDB 496; EINECS 215-785-7; C42H62O16; Glycyrrhizin [JAN]; NSC 167409; NSC 234419; BRN 0077922; CHEMBL441687; NSC 2800; beta-Glycyrrhizin; CHEBI:15939; 6FO62043WK; DSSTox_RID_82047; DSSTox_CID_27006; DSSTox_GSID_47006; Glycyram; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C42H62O16
|
||||
| InChI |
InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1
|
||||
| InChIKey |
LPLVUJXQOOQHMX-QWBHMCJMSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
| DrugBank ID | |||||
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Drug
| In total 1 item(s) under this drug | ||
| Crosstalk ID: M6ACROT05266 | ||
| m6A Regulator | Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) | |
| m6A Target | High mobility group protein B1 (HMGB1) | |
| Epigenetic Regulator | hsa-miR-320a-3p | |
| Regulated Target | Insulin like growth factor 2 mRNA binding protein 3 (IGF2BP3) | |
| Crosstalk relationship | ncRNA → m6A | |
| Disease | Bladder cancer | |